Biopharmas use leading CTMS for improved trial
efficiency and collaboration
BARCELONA, Spain, Jan. 29,
2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today
announced that more than 200 companies – including 17 of the top 20
biopharmas – use Veeva CTMS to execute faster, more efficient
trials. As study complexity and data volumes increase, biopharmas
and CROs are centralizing data and documents with Veeva CTMS to
streamline processes and drive stakeholder collaboration.
"Veeva CTMS is the central hub of our trials, allowing study
metrics and documents to flow seamlessly across our ecosystem,"
said Bonne Adams, vice president of operations at Inhibrx. "Using
clinical applications on a connected platform saves time and effort
for our lean team and improves how we work with CRO partners."
Whether biopharmas insource or outsource trials, clinical teams
can use Veeva CTMS to proactively manage studies and quickly
identify and address issues. With a flexible and scalable system,
companies can accelerate trial execution and deliver high-quality
data while maintaining compliance with global regulations like ICH
E6(R2) and (R3).
To help biopharmas adapt to trial operating model changes and
keep up with evolving regulations, Veeva continues to deliver
clinical innovations. New Veeva CTMS advancements include:
- CTMS transfer automates daily data transfers from CROs to
sponsors for greater visibility
- Oversight issue tracking and management for faster
resolution
- Enhancements to manage insourced, outsourced, and complex
trials for speed and agility
"Modern clinical trial management systems should scale easily
and support both insourced and outsourced operating models," said
Henry Galio, vice president of Veeva
CTMS strategy. "To provide this flexibility, we're delivering new
capabilities for Veeva CTMS through our three product releases per
year, continuously advancing to help the industry work better
together and accelerate execution."
With the increased adoption of Veeva CTMS, more companies are
simplifying trial operations and maintaining compliance regardless
of operating model. Veeva CTMS is part of Veeva Clinical Platform,
the most complete and highest-quality platform for faster and more
efficient trials. Learn more at Veeva R&D and Quality
Summit, Europe. Life sciences
industry professionals can register for the 4-5 June
event in Madrid.
Additional Information
For more on Veeva CTMS, visit:
veeva.com/eu/CTMS
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com/eu.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and services
and the expected results or benefits from use of our products and
services. These statements are based on our current expectations.
Actual results could differ materially from those provided in this
release and we have no obligation to update such statements. There
are numerous risks that have the potential to negatively impact our
results, including the risks and uncertainties disclosed in our
filing on Form 10- Q for the period ended October 31, 2024, which you can
find here (a summary of risks which may impact our
business can be found on pages 36 and 37), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/more-than-200-companies-advance-trial-management-with-veeva-ctms-302362855.html
